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Abstract: This paper tells the story of how hormesis became recognized as a fundamental concept
in biology, affecting toxicology, microbiology, medicine, public health, agriculture, and all areas
related to enhancing biological performance. This paper assesses how hormesis enhances resilience to
normal aging and protects against a broad spectrum of neurodegenerative, cardiovascular, and other
diseases, as well as trauma and other threats to health and well-being. This paper also explains the
application of hormesis to several neurodegenerative diseases such as Parkinson’s and Huntington’s
disease, macrophage polarization and its systematic adaptive protections, and the role of hormesis in
enhancing stem cell functioning and medical applications.
Keywords: hormesis; dose response; adaptive response; pre-conditioning; biphasic; resilience;
hormetic
1. Introduction
The dose response concept is central to biology, medicine, and public health [1]. It represents
the biological integration of how living systems at all levels of organization, from the cell to the
individual, respond, adapt or fail to adapt to endogenous agents, metabolic processes, and externally
imposed stressors/threats. The dose response can capture and provide biological/mechanistic insight
to such challenges when assessed as a dose-time response that describes dynamic processes such as
the induction of toxicity, repair, and recovery [2]. Biological systems are therefore dynamic entities
with an evolutionary adaptive strategy, which is reflected in the nature of the dose-time response.
2. Dose Response in Historical Context
Within this context consider how the radiation genetics research community approached the
concept of dose response for radiation-induced mutation which was discovered by Muller [3].
Within three years of this discovery Muller [4] proposed the so-called “Proportionality Rule”, that
the dose response for X-ray induced mutation was linear down to a single ionization for all cell
types [5,6]. This perspective would subsequently lead to the creation of the linear non-threshold
(LNT) model for low dose risk estimation [7]. The Proportionality Rule was widely viewed as
credible by the contemporary radiation genetics community and eventually would be accepted by
the US National Academy of Sciences (NAS) Biological Effects of Atomic Radiation (BEAR) Genetics
Panel [8], whose recommendations lead to the adoption of the LNT model for cancer risk assessment
worldwide. The Proportionality Rule and its direct regulatory dose response progeny, the LNT cancer
risk model, were products of a series of three key assumptions that all induced genetic damage was:
(1) unrepairable; (2) irreversible; and (3) cumulative. This collective and integrative set of functional
assumptions lead to the belief that the dose response would be linear for ionizing radiation and
chemical-induced mutation and carcinogenesis.
This dose response hypothesis was based on the study of mutations in mature spermatozoa of
Drosophila. At the time of this hypothesis formation and its applications to risk assessment, it was
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not known that DNA repair existed let alone that it became lost or fully degraded as spermatogonia
transitioned to mature spermatozoa. Thus, when the US NAS Genetics Panel [8] made their seminal
recommendation that regulatory agencies adopt the LNT model for risk assessment they were fully
committed to the belief that X-rays and chemical mutagens would cause mutations that could never be
repaired and that any induced damage would be cumulative and the dose response linear. So firm were
these beliefs within the radiation genetics community that these incorrect convictions quickly became
public policy, remaining so even today, as reflected in national regulatory risk assessment policies.
This belief in linearity at low doses would be challenged by another contemporary prominent
radiation geneticist, William Russell, Oak Ridge National Laboratories, using the mouse specific locus
test with over two million mice in his iterative radiation-induced mutational studies (see [9,10] for
a detailed review). In this case, Russell [11,12] employed mouse spermatogonia (rather than the
mature spermatozoa) as the stage of reproductive cell exposure. Russell discovered the concept of
dose rate, that is, the mutation damage was not cumulative but a function of the rate at which the
radiation was applied. This finding was directly contradictory to the longstanding geneticist mantra of
irreversible, cumulative, and linear. Based on his dose rate studies Russell [13] reported that female
mice, even when administered a radiation dose some 27,000 times greater than background ionizing
radiation, displayed a mutation response that was not greater than the mutation rate of the unexposed
controls. This dose-time experiment would reveal that the oocytes were not static cells but able to
prevent/repair fully the effects of even relatively high doses of radiation. These observations as well
as those with spermatogonia lead Russell to propose the existence of DNA repair processes. Within the
next four year’s such DNA repair processes were shown to exist, be very general and eventually
lead to the discovery of constitutive and inducible repair processes and to an eventual Nobel Prize
in 2015. These findings would also lead to the recognition that mature spermatozoa lack such DNA
repair but that this deficit is compensated by repair capacities provided by the ovum during the
reproductive process.
The Russell et al. [12] dose rate discovery was a seminal event and led to the recognition that
the US NAS BEAR Genetics Panel [8] made an error in their extrapolation of responses in mature
spermatozoa to all cells, including somatic cells. These findings of Russell revealed that the linear dose
response mantra of the radiation geneticists was no longer valid [14,15]. This BEAR Genetics Panel
error [8], which was recognized by the next US NAS BEIR (Biological Effects of Ionizing Radiation)
Committee [16], was of fundamental importance as it incorrectly provided the scientific foundation
for the linear dose response for mutation and cancer risk assessment. Not recognized by the BEIR
Committees (1972 to the most recent 2006) was that Muller’s assertion that he had produced gene
mutations in his 1927 published research was also incorrect. Based on modern nucleotide analyses
Muller’s mutations were not gene mutations but genetic alterations at the level of chromosome
due principally to modest to massive gene deletions [17]. The LNT model was therefore derived
based on the incorrect assumption that Muller had induced gene mutations. Either of these errors
(i.e., extrapolating from mature spermatozoa to somatic cells and the gene mutation interpretation
mistake) would invalidate the LNT model.
The Russell findings would also provide the foundation for subsequent research which
demonstrated the existence of the adaptive/repair responses for chemically induced mutations in
the mid-1970s [18] and later for ionizing radiation [19]. These adaptive response/preconditioning
protective findings were significant not only because they affected mutation production, which was
considered the underlying mechanism of cancer, but because they paved the way for extending
the preconditioning concept to a vast range of other diseases and injuries that could be
prevented/minimized by hormetic strategies [9,10].
The existence of a broad spectrum of DNA repair and other adaptive processes lead to the belief
that the linear dose response was at best extremely limited, with little or no application to complex
biological systems [20]. The discovery of various classes of protective mechanisms also led to new dose
response models or giving old dose response models a second look. Within the framework of ionizing
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radiation exposures were the dramatic findings of Azzam et al. [21] that very low doses of radiation had
the capacity to upregulate DNA repair processes leading to a significantly lower amount of mutational
damage than found in the normal controls, thereby suggesting the existence of an hormetic-biphasic
dose response. Furthermore, numerous studies have shown that removal of background radiation
from the environment of various experimental models leads to striking degradations of health status,
which is reversible with the reinstituting of the background radiation [22,23].
3. The Hormesis Concept
This brief historical vignette into the foundations of the radiation genetics-mutation story
demonstrates that this research community had a concept that biological systems, from cells to whole
organisms, were static rather than dynamic. It was also curious that these evolutionarily-based
radiation geneticist researchers would not have assumed that selection for genetic repair
processes would have occurred during evolution and be reflected in the mutation dose response.
Of particular note is that the developments of Russell, Samson and Cairns [18], Olivieri et al. [19],
and Azzam et al. [21] suggested that dose responses in the low dose zone were not only not linear but
possibly not even a threshold but probably biphasic (i.e., J-shaped or inverted U-shaped depending on
the endpoint graphed). These findings were supported subsequently by massive summaries of ionizing
radiation dose response information provided in seminal books by Luckey [24,25]. These books
supported the premise that the hormetic dose response was so common in the scientific literature that
hormesis should have been an evolutionary expectation rather than an exception, methodological
error, or a response confused with background variation.
The gradual unfolding of the widespread nature of the hormetic dose response in the radiation
genetics community would also occur in other areas of the biological and biomedical sciences from the
late 1970s to the present. These researchers developed new analytic tools to measure progressively
lower doses of chemical agents and exploited the in vitro revolution of the 1980s which permitted the
testing of a large number of concentrations across broad concentration ranges. These developments
are reflected in the number of citations with the term hormesis or hormetic on a yearly basis in the
Web of Science data base. During the entire decade of the 1980s this number was about 10–12 citations
per year whereas in 2017 alone this number increased dramatically to over 9300, reflecting a highly
interdisciplinary reporting of hormetic dose responses with a strong mechanistic framework.
4. How Medicine, Pharmacology, and Toxicology Got the Dose Response Half-Wrong
While the hormesis concept was markedly accelerated by the above developments in cellular
models and evaluation methods, the concept of hormesis is about 130 years old, starting with the
findings of Hugo Schulz [26,27] concerning the effects of nearly a dozen disinfectants on yeast
metabolism. Schulz’s research was significant as it established the biphasic dose response within
the framework of a modest overcompensation response to an initial disruption in homeostasis.
This research revealed the capacity of the organism to display an initial harmful response to toxic
agents and to respond to such-induced damage with a modest reparative overcompensation (i.e., a low
dose stimulation). Despite the fact that Schulz’s work was replicated by multiple groups [28] and
broadly extended and generalized [29–33], Schulz made a fundamental error soon after his discovery
by associating his biphasic dose response with the practice of homeopathy, asserting that he had
discovered its explanatory principle [34]. This action of Schulz created a prolonged scientific and
professional/personal backlash from the powerful traditional medical community curtailing his career
and profoundly blunting acceptance of the biphasic dose response/hormesis concept [34–36].
Even though Schulz and his biphasic dose response (which he termed the Arndt-Schulz Law)
would be stridently and unrelentingly challenged and ridiculed by leaders within traditional
medicine [37–39], many independent investigators during Schulz’s professional career (1880 to
1932) would report similar biphasic dose response findings employing various biological models,
especially in the fields of microbiology, plant biology, and entomology, using numerous chemicals
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and ionizing radiation [29–33]. However, for a variety of reasons (Calabrese [5,36]) the biphasic dose
response concept continued to be marginalized, never integrated within the scientific mainstream.
This would eventually begin to change in the 1970s as a result of the scientific leadership of Luckey [24],
University of Missouri, with respect to ionizing radiation, Tony Stebbing [40,41], Plymouth Marine
Research Station (UK), who studied heavy metal marine toxicology and Elmer Szabadi [42], University
of Liverpool, who reported a large number of pharmacologically-based biphasic dose response
relationships, placing them within a receptor based mechanistic framework. These three independent
investigators provided the key intellectual foundations for the hormetic biphasic dose response
transformation, which was sparked by the first hormesis conference that was held in Oakland,
California in August, 1985 (with the peer reviewed proceedings published in the journal Health
Physics in 1987).
The next several decades would provide substantial documentation that hormetic dose responses
were common, and occurred in a broad range of microbial, plant, and animal models, suggesting
widespread generality [43–45]. Likewise, the occurrence of hormetic responses could be induced
by a wide range of agents, affecting a similarly wide range of endpoints [46–48]. These efforts led
to the development of a continuously expanded hormesis data base that includes information on
approximately 40 study related experimental and dose response features.
Despite the considerable diversity of biological models, inducing agents, and endpoints showing
hormetic dose responses, they have one highly consistent characteristic in common, that is, their
quantitative features are similar. This was also the case whether the low dose stimulation occurred via
a direct stimulation or via an overcompensation to an initial toxicity response [49]. The stimulatory
response magnitude at maximum was typically modest, with a maximum range of about 30–60%
greater than the control group. This finding was reaffirmed as the number of hormetic studies increased
from hundreds to many thousands, it being the most predictable feature of hormesis. This modest
stimulatory response was independent of biological model, level of biological organization, endpoint
and inducing agent. It was later shown to be independent of mechanism [50]. This further suggested
that hormesis was providing a quantitative description of a form of biological plasticity [51].
These biologically profound developments occurred via the study of vast numbers of dose
responses and their quantitative, and mechanistic features. Furthermore, the quantitative features
of the hormetic dose response also were biologically modeled and reflected an allometric pattern
that was similar to those that relate a vast range of key biological parameters to body weight and/or
body surface [6]. These collective developments indicated that hormesis is a fundamental principle
in biology, the product of natural selection and highly conserved. This biological principle had been
overlooked by multiple generations of biological and biomedical scientists due, in large part, to the
prolonged conflict between homeopathy and traditional medicine, the exclusion of the hormesis
concept from mainstream scientific activities, and inherent challenges in studying modest responses at
relatively low doses [34]. These key features, understandings and insights have been added since the
mid-1990s as a result of the long term consistent focus on hormesis.
Since hormesis defines the magnitude and limits of biological plasticity it has widespread
and significant implications for drug development, disease resistance and other activities designed
to enhance biological performance and to acquire resilience via procedures such as pre-and
post-conditioning [9,10]. Since the constraints of plasticity are defined by the quantitative features of
the hormetic dose response this perspective can inform the pharmaceutical and agrochemical industries
that biological performance is maximally limited to the 30–60% range, having important implications
for study designs and commercial product exploration in the clinic, laboratory, and field studies.
The evaluation of the maximum hormetic stimulatory response represents a type of biological
optima. Exactly where that optimal hormetic stimulation response resides in the zone below the
threshold is important to determine in the testing of possible therapeutic agents. It is frequently located
in a zone usually 10–20 fold below the estimated threshold. Using the hormesis data base [46,47] we
have evaluated whether the number of doses below the threshold may affect the capacity to detect
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the optimal dose (i.e., dose predicting the maximum stimulatory response). This set of evaluations
revealed that with one dose below the threshold the maximum observed stimulatory response was
approximately 20% above the control response. As the number of doses below the threshold increased
to 6–7 the maximum observed stimulatory response progressively increased to approximately 60%
greater than the control value. Thus, the tendency of clinical trials to use one to two doses suggests
that such studies will yield a lower maximum stimulation than biologically possible. This suggests the
need for either a larger sample size to detect a significant treatment effect and/or additional treatment
groups within the hormetic zone. This insight into how the number of number of doses below the
threshold affects the maximum hormetic stimulation may become a factor for those interested in
assessing hormetic doses response in all types of studies as this relationship occurred whether the
studies were conducted in vitro or in vivo and independently of biological model and endpoint.
5. Hormetic Applications
The hormetic dose response has important implications for the fields of hazard assessment, risk
assessment for carcinogens, endocrine disruption, for pharmaceuticals/natural products that enhance
biological performance, and pre/post conditioning activities that upregulate adaptive mechanisms,
enhancing resilience.
5.1. Hazard Assessment
Hormesis is helpful in guiding the hazard assessment process in several ways. It provides
a scientific basis for the selection of biological models for evaluation especially as it relates to
background disease incidence. It provides a dose response model framework to assist in the
selection of the number of doses, the dose spacing, and sample sizes to be employed. Hormesis
also affects decisions concerning repeat sampling over time to assess possible compensatory responses.
These hormetic-based insights are useful and likely to enhance the quality and utility of such studies,
increasing confidence in the findings while also providing biostatistical model validation. Nonetheless,
these factors can be problematic since they make experiments more expensive and longer to complete.
Furthermore, in order to be successful in locating doses below the threshold one must know where
the threshold is likely to occur in order to better target the low dose hormetic stimulatory zone with
appropriate study designs. This would also usually require additional preliminary experiments to
better clarify the dose zone within which a threshold may be likely to occur. These experimental
challenges can make it difficult to assess hormetic hypotheses and to provide reproducible findings
for low dose responses. This can be troublesome if the control group is especially variable. Further,
it is important to have well documented information on control group variation. Failure to take
such factors into consideration has the potential to reduce confidence concerning whether observed
hormetic-like biphasic dose responses are reproducible effects or simply due to background variation.
5.2. Risk Assessment for Carcinogens
It has recently been proposed that regulatory agencies such as the Environmental Protection
Agency (EPA) move away from their use of the LNT as the default model in cancer risk assessment and
consider the use of non-linear dose response models such as hormesis. Calabrese et al. [52] proposed
that this EPA proposal could be implemented with a “model optimization” approach that integrates
the best features of the LNT, threshold, and hormetic models. We have previously shown that using
a Bench Mark Dose (BMD) plus a 100 fold uncertainty factor method as is typically used for a chronic
toxicity threshold risk assessment method closely approximates the same dose at the nadir of the
hormesis curve where health benefits are optimized [53]. This dose also represents an LNT risk of about
10−4 (Figure 1). This model uncertainty approach therefore identified a type of regulatory sweet spot
wherein the population risk increases when the dose changes either up or down from the optimized
dose at the nadir of the hormetic curve. In this approach, the LNT may be considered as the upper
bound of uncertainty while the hormetic model would represent the lower bound. This approach also
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provides a type of dose convergence validation of the hormetic approach via the threshold model
even though the risk interpretations differ at the optimized dose. If the hormetic model were correct,
large health benefits would accrue to the population at risk. However, if the hormetic model were
incorrect and the LNT were fully correct, the effects could not even be detected by the most powerful
epidemiological studies. In fact, the increased risk would still be about 1/500 of the background
cancer risk, thereby making this model uncertainty approach for cancer risk assessment practical and
attractive from a public health perspective.
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5.3. Harmful Effec s of Hormesis
Low doses of some endocrine disrupting agents act via biphasic dose responses that conform very
closely to the quantitative features of the hormetic dose response. For example, in some animal models
low doses of bisphenol A (BPA) biphasically affected prostate size, with a maximum enhanceme t in
the hormetic response zo e [54]. A similar type of hormetic-lik biphasic biologic l response ccurs for
many anti-tumor drugs when tested on dozens of human tumor cells lines [55]. Similar hormetic effects
have lso been reported for larg numbers of antibiotics in broad screening assays [56]. There are
numer u other types of examples whe e the lo dose stimulation is considered an adverse effect [44].
The agnitude of these effects are also constraine by the bounds of biological plasticity.
5.4. Pharmaceutical Products
A wide range of pharmaceutical products display hormetic features, including anxiolytic
(Figure 2) [54] and anti-epileptic (Figure 3) [57] drugs. In preclinical studies, these agents uniformly
exhibit hormetic dose responses. Based on these findings with animal models, the optimized dose
would be selected for testing within hum n subjects. Thus, the pharmaceutical industry has substantial
areas of its product portfolio based on th hormetic dose response. The area of memory enhancing
drugs likewise display th horm tic dos response [58]. All Alzheimer’s Disease (AD) drugs approved
for h man use by he US FDA (Food and Drug Administration) display t e hormeti dose response
in their preclinic l findings [58]. While there has been intens research activity on how to prevent
th accumulation of b ta-amyloid plaques in the brains of AD patients, beta amyloid has essential
biolo ic l functions and acts in a hormetic-biphasic fashion [59] (Figure 4), finding that ave been
emphasized in the AD research community but yet still remains little app ci ted nor clinically
exploit d. Furthermore, the longes approve drug for the treatment of ALS (amyotrophic lateral
sclerosis) is riluzole [60], which has its protective fun tions medi ted via the ind ction of hormetic
processes (Figure 5).
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5.5. Parkinson’s Disease and Huntington’s Disease
The search for viable treatments for Parkinson’s and Huntington’s Diseases (HD) use a variety of
predictive experimental models. Calabrese et al. [61,62] have reported the widespread occurrence of
promising chemopreventive agents for Parkinson’s Disease (PD). In this assessment, approximately 50
agents were found to affect chemoprotection via hormetic processes (Figures 6 and 7) [62]. The large
number of hormetic examples of possible PD agents has been enhanced by the use of cellular model
systems that incorporated relatively large numbers of concentrations, permitting more detailed
evaluations of the dose response features in the therapeutic zone. This offers a novel effort to
explore, evaluate and frame potential drug discovery and therapeutic applications within an hormetic
framework. This has also been the case with HD with numerous examples of hormesis biphasic dose
responses in in vitro (Figure 8) [63] and in vivo experimental models (Figure 9) [64]. In the case of both
PD and HD the experimental protocols have made extensive use of hormetic-preconditioning protocols.
Other experimental protocols have also demonstrated hormetic effects when the administration
occurred at the initiation of the disease process or within post-conditioning frameworks. The capacity
of the agents to activate hormetic processes within such a range of disease activating protocols is
an important observation as it indicates that hormesis may be employed in prevention as well as
therapeutically. Similar developments are also being reported within predictive models for other
neurological diseases such as Multiple Sclerosis [65,66].
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6. Hormetic Mechanisms
The role of mechanism in hormesis has shown marked advances over the past decade. During the
1990s as the concept of hormesis was beginning to be explored in depth, there were many reproducible
examples of hormesis, but any mechanistic basis for such responses was very limited and often
speculative. This has changed with major advances in the area of cell signaling pathways and their
linkage with receptors activating biological processes. In 2013, Calabrese [50] documented mechanisms
for 400 different hormetic dose response relationships at the level of receptor and cell signaling
pathways. This assessment indicated that a vast range of mechanisms mediate hormetic responses.
The quantitative features of the hormetic dose responses were independent of mechanism. This raises
the question of why and how the quantitative features of hormesis are so similar across phyla, organs,
cell types, endpoints, and proximate mechanisms within this context. Calabrese and Mattson [51] have
identified possible regulatory biological processes emerging from allometric gene clusters. These genes
regulate key biological traits such as the relationship of size of organs to overall body size. Hormetic
dose responses also conform to allometric modelling and may be assessed within this biologically
based allometric architectural gene cluster framework. These types of traits provide insights on overall
form and function parameters from single celled organisms to humans and may offer clues to the
basis for how the 30–60% increase in hormetic maximal responses occur that are independent of
proximate mechanisms.
Macrophage Polarization
A major development over the past two decades has been the recognition that macrophages
can be reprogrammed toward pro-oxidative (called M1 macrophages) or anti-inflammatory forms
(called M2 macrophages). In the case of preconditioning, this process acts to polarize macrophages
toward the M2 form, facilitating protective/reparative/anti-inflammatory responses. We have recently
hypothesized that macrophage reprogramming with polarization to M1 or M2 macrophage forms
may be mediated via concentration gradients of signaling agents. A comprehensive assessment
revealed many substances can mediate macrophage polarization following a concentration gradient
that conforms to an hormetic dose response [70,71]. This concentration gradient regulatory strategy is
widespread, affecting all organs. The initial incentive to explore this area was based on observations
that low doses of radiation kills tumor cells while also ameliorating inflammatory conditions via
the creation of anti-inflammatory phenotypes [72,73]. In the attempt to better understand the
occurrence of radiation induced pro-oxidative and anti-inflammatory phenotypes, the challenge
became greatly expanded as noted above. The integration of the hormesis concept within macrophage
polarization reveals that inflammatory processes can be regulated as to facilitate the elimination of
tumor cells and harmful microbes or conversely to suppress inflammatory processes and enhance
healing via a concentration gradient process. These findings expand the biomedical/therapeutic
significance of the hormetic concept within the context of biological regulatory processes and their
biological/clinical applications.
7. Stem Cell Biology & Hormesis
A substantial literature exists on the occurrence of hormetic dose responses in a broad spectrum
of stem cells. These stem cell hormetic responses have involved both direct stimulatory dose response
features as well as those induced within a preconditioning framework. The quantitative features of
the hormetic dose response for stem cells are similar to all other cell types [47]. Particular interest
has focused on preconditioning-hormetic protocol with stem cells within a potentially therapeutic
framework of tissue regeneration following damage from various conditions such as heart attack or
stroke. The preconditioning hormetic process is expected to enhance the capacity of the injected stem
cells to better survive very challenging biological micro-environments and enhance the likelihood of
tissue repair [74–78]. An assessment of the Hormesis Database indicates that several dozen agents
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have induced hormesis in stem cells, with the most extensive research efforts with ionizing radiation,
hypoxia, and resveratrol.
8. Discussion/Conclusions
This paper is set within the theme of this special journal issue—“day break hormesis”.
Even though hormesis is scientifically “coming of age” it was first reported in the 1880s, with
considerable research providing a large number of well executed studies through the past century
in many biological areas [29,30,46,47]. Thus, one would have thought that the dawn of hormesis
should not have been so drastically delayed, nor a fundamental biological principle missed by the
scientific community for over a century. These bizarre historical circumstances would probably not
have occurred had Hugo Schulz not associated hormesis with homeopathy and if homeopathy had
not been in a major economic and intellectual war with what may be called traditional medicine [35].
While homeopathy was severely defeated in this real conflict, traditional medicine extended its hostility
to its “explanatory principle”, the hormesis concept. Thus, via the leadership of key world leaders
in the pharmacology community, such as Alfred J. Clark, homeopathy became nearly dismantled as
a medical practice and Schulz would see a very fast rising career, quickly stalled and never to recover.
In fact, in the US there were 23 homeopathic medicine schools in 1900 and only three about 20 years
later [79,80]. As the fate of homeopathy was in a strongly downward spiral so to was its “explanatory
principle”. Hormesis would not be found in any of the leading textbooks; it was excluded from research
funding, and faculty at leading institutions were strongly discouraged from studying it. In effect,
an idea was given a type of death sentence. This was as true academically as it has been in regulatory
agencies worldwide. On top of this nearly impossible situation, the study of hormesis was also very
challenging, requiring more doses, larger sample sizes, greater need for replication, and even more
preliminary investigations to better identify the threshold zone. Superimposed on these problems was
a dire lack of leadership and organization by those researching in this area. This has been investigated
to a considerable depth and it was found that many of the leading hormesis researchers in the 1920s
and 1930s moved to major institutional administrative positions, denying this troubled fledgling area
the chance to grow [36]. What this amounted to was the failure of the scientific community to study,
assess, and possibly recognize the significance of hormesis. In a great irony, this failure to grasp the
hormesis concept occurred as a result of traditional medicine winning its battle with homeopathy.
That is, traditional medicine won the war, but hurt its profession and the public with the discrediting
of the hormesis concept. Making this situation even more problematic is that a vast number of terms
can be used to describe the hormesis dose response. In fact, the very large hormesis data base [47]
contains information from studies in which hormesis or hormetic were used as key words for only
about 15% of the entered studies. Thus, hormetic dose responses are not easily found in the literature
using the two key words: hormesis or hormetic.
The past century of challenges to hormesis has become less influential with its effects becoming
diluted in an asymptotic-like regression. The past 30 years of intense research focus on hormesis
has worked its way through this quagmire of historical antipathies and scientific challenges, with
major advances establishing the generality of hormesis and its potential medical, public health,
and agricultural implications.
Hormesis is now becoming prominent in leading textbooks in toxicology, pharmacology,
and related biomedical areas. It has greatly profited from outstanding leadership in the areas of
biogerontology, neuroscience/neurodegenerative diseases, exercise science, and other areas of public
health interest. Hormesis is becoming seen as a central biological concept that can help researchers
answer key biological questions in many domains. Thus, while it has been a 130 year wait, I am sure
that Hugo Schulz would be proud that hormesis has finally reached its own scientific tipping point as
reflected in this special issue on day break hormesis.
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